Translocation of gut microbiota in liver cirrhosis: mechanisms, clinical significance, and markers

I. Gavrilenko Dmitrii; N.N.  Silivontchik

doi:10.36488/cmac.2021.2.147-160

Translocation of gut microbiota in liver cirrhosis: mechanisms, clinical significance, and markers

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(2):147-160

Gavrilenko D.I., Silivontchik N.N.

10.36488/cmac.2021.2.147-160

liver cirrhosis gut microbiota bacterial translocation markers lipopolysaccharide infection mortality

Section

Diseases and Pathogens

Type

Review

Publication

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(2):147-160

Abstract Authors Literature PDF Statistics

Abstract

This article is an overview of the data on bacterial intestinal translocation. The article reviews changes in the intestinal microbiome, the local physiological barrier, as well as the innate and adaptive immunity characteristics contributing to the liver cirrhosis development and progression. The results of published studies on the assessment of potential bacterial translocation markers (C-reactive protein, procalcitonin, lipopolysaccharide, presepsin etc.) and their use to predict infection and mortality in patients with liver cirrhosis are presented. The up-to-date methods to study the intestinal microbiome as well as some directions for future research are also described.

Dmitrii I. Gavrilenko

dm.gavrilenko891@gmail.com

Republican Research Centre for Radiation Medicine and Human Ecology, Gomel, Republic of Belarus

Silivontchik N.N.

Belarusian Medical Academy of Postgraduate Education, Minsk, Republic of Belarus

1. Soares-Weiser K, Brezis M, Tur-Kaspa R, Leibovici L. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev. 2002;(2):CD002907. DOI: 10.1002/14651858.CD002907
2. Cohen M.J., Sahar T., Benenson S., Elinav E., Brezis M., Soares-Weiser K. Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev. 2009;(2):CD004791. DOI: 10.1002/14651858
3. Bunchorntavakul C., Chamroonkul N., ChavalitdhamrongD. Bacterial infections in cirrhosis: a critical review and practical guidance. World J Hepatol. 2016;8(6):307-321. DOI: 10.4254/wjh.v8.i6.307
4. Bartoletti M., Giannella M., Lewis R.E., Viale P. Bloodstream infections in patients with liver cirrhosis. Virulence. 2016;7(3):309-319. DOI: 10.1080/21505594.2016.1141162
5. Jalan R., Fernandez J., Wiest R., Schnabl B., Moreau R., Angeli P., et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310-1324. DOI: 10.1016/j.jhep.2014.01.024
6. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol. 2005;42(Suppl. 1):S85-S92. DOI: 10.1016/j.jhep.2004.12.006
7. Wong F., Bernardi M., Balk R., Cristman B., Moreau R., Garsia-Tsao G., et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club Gut. 2005;54(5):718-725. DOI: 10.1136/gut.2004.038679
8. Berg R.D., Garlington A.W. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun. 1979;23(2):403-411. DOI: 10.1128/iai.23.2.403-411.1979
9. Guarner C., Runyon B.A., Young S., Heck M., Sheikh M.Y. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol. 1997;26(6):13721378. DOI: 10.1016/s0168-8278(97)80474-6
10. Steffen E.K., Berg R.D., Deitch E.A. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis. 1988;157(5):1032-1038. DOI: 10.1093/infdis/157.5.1032
11. Cirera I., Bauer T.M., Navasa M., Vila J., Grande L., Taurá P., et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol. 2001;34(1):32-37. DOI: 10.1016/s0168-8278(00)00013-1
12. Pande C., Kumar A., Sarin S.K. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther. 2009;29(12):12731281. DOI: 10.1111/j.1365-2036.2009.03994
13. Feng Q., Chen W.D., Wang Y.D. Gut microbiota: an integral moderator in health and disease. Front Microbiol. 2018;9:151. DOI: 10.3389/fmicb.2018.00151
14. Konturek P.C., Harsch I.A., Konturek K., Schink M., Konturek T., Neurath M.F., et al. Gut-liver axis: how do gut bacteria influence the liver? Med Sci (Basel). 2018;6(3):79. DOI: 10.3390/medsci6030079
15. Krause W., Matheis H., Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet. 1969;1(7595):598-599. DOI: 10.1016/s01406736(69)91534-7
16. Sekirov I., Russell S.L., Antunes L.C., Finlay B.B. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859904. DOI: 10.1152/physrev.00045.2009
17. Hsieh W.J., Lin H.C., Hwang S.J., Hou M.C., Lee F.Y., Chang F.Y., Lee S.D. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol. 1998;93(6):962-966. DOI: 10.1111/j.15720241.1998.00288.x
18. Mackay A.D., Taylor M.B., Kibbler C.C., HamiltonMiller J.M. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect. 1999;5(5):290-292. DOI: 10.1111/j.1469-0691.1999.tb00144.x
19. Rautio M., Jousimies-Somer H., Kauma H., Pietarinen, I., Saxelin M., Tynkkynen S., Koskela M. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis. 1999;28(5):11591160. DOI: 10.1086/514766
20. Oliveira J.D.C, Carrera E., Petry R.C., Deutschendorf C., Mantovani A., Thifani S., et al. High prevalence of multidrug resistant bacteria in cirrhotic patients with spontaneous bacterial peritonitis: is it time to change the standard antimicrobial approach? Can J Gastroenterol Hepatol. 2019;2019:6963910. DOI: 10.1155/2019/6963910
21. Fernández J., Bert F., Nicolas-Chanoine M.H. The challenges of multi-drug-resistance in hepatology. J Hepatol. 2016;65(5):1043-1054. DOI: 10.1016/j.jhep.2016.08.006
22. Moreau R., Elkrief L., Bureau C., Perarnau J.-M., Thévenot T., Saliba F., et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology. 2018;155(6):1816-1827.e9. DOI: 10.1053/j.gastro.2018.08.026
23. Fernández J, Navasa M, Planas R, Montoliu S., Monfort D., Soriano G., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133(3):818-824. DOI: 10.1053/j.gastro.2007.06.065
24. Gavrilenko D.I, Silivonchik N. The structure and antibiotic resistance of infectious pathogens in hospitalized patients with decompensated cirrhosis. Klinicheskaja infektologija i parazitologija. 2015;2:34-45. Russian.
25. Sugihara T., Koda M., Maeda Y., Matono T., Nagahara T., Mandai M., et al. Rapid identification of bacterial species with bacterial DNA microarray in cirrhotic patients with spontaneous bacterial peritonitis. Intern Med. 2009;48(1):310. DOI: 10.2169/internalmedicine.48.1539
26. Lata J., Stiburek O., Kopacova M. Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis. World J Gastroenterol. 2009;15(44):5505-5510. DOI: 10.3748/wjg.15.5505
27. Piano S., Singh V., Caraceni P., Maiwall R., Alessandria C., Fernandez J., et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology. 2019;156(5):1368-1380.e10. DOI: 10.1053/j.gastro.2018.12.005
28. Yan A.W., Fouts D.E., Brandl J., Stärkel P., Torralba M., Schott E., et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology. 2011;53(1):96-105. DOI: 10.1002/hep.24018
29. Fouts D.E., Torralba M., Nelson K.E., Brenner D.A., Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012;56(6):1283-1292. DOI: 10.1016/j.jhep.2012.01.019
30. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031. DOI: 10.1038/nature05414
31. Kristensen N.B., Bryrup T., Allin K.H., Nielsen T., Hansen T.H., Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 2016;8(1):52. DOI: 10.1186/s13073016-0300-5
32. Dhiman R.K., Rana B., Agrawal S., Garg A., Chopra M., Thumburu K., et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology. 2014;147(6):1327-1337. DOI: 10.1053/j.gastro.2014.08.031
33. Bajaj J.S., Heuman D.M., Hylemon P.B., Sanyal A.J., Puri P., Sterling R.K., et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther. 2014;39(10):1113-1125. DOI: 10.1111/apt.12695
34. Tandon P., Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28(1):26-42. DOI: 10.1055/s-2008-1040319
35. Fiuza C., Salcedo M., Clemente G., Tellado J.M. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis. 2000;182(2):526-533. DOI: 10.1086/315742
36. Panés J., Pérez-del-Pulgar S., Casadevall M., Salas A., Pizcueta P., Bosch J., et al. Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat. Hepatology. 1999;30(2):445-453. DOI: 10.1002/hep.510300214
37. Brann O.S. Infectious complications of cirrhosis. Curr Gastroenterol Rep. 2001;3(4):285-292. DOI: 10.1007/s11894-001-0051-2
38. Christou L., Pappas G., Falagas M.E. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol. 2007;102(7):1510-1517. DOI: 10.1111/j.1572-0241.2007.01286.x
39. Prodanovic H., Cracco C., Massard J., Barrault C., Thabut D., Duguet A., et al. Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series. BMC Gastroenterol. 2007;7:2. DOI: 10.1186/1471-230X-7-2
40. Falcone M., Massetti A.P., Russo A., Vullo V., Venditti M. Invasive aspergillosis in patients with liver disease. Med Mycol. 2011;49(4):406-413. DOI: 10.3109/13693786.2010.535030
41. Cho Y.J., Lee S.M., Yoo C.G., Kim Y.W., Han S.K., Shim Y.S., et al. Clinical characteristics of tuberculosis in patients with liver cirrhosis. Respirology. 2007;12(3):401-405. DOI: 10.1111/j.1440-1843.2007.01069.x
42. Chou C.H., Ho M.W., Ho C.M., Lin P.-C., Weng C.-Y., Chen T.-C., et al. Abdominal tuberculosis in adult: 10year experience in a teaching hospital in central Taiwan. J Microbiol Immunol Infect. 2010;43(5):395-400. DOI: 10.1016/S1684-1182(10)60062-X
43. Gavrilenko D.I. Acute miliary tuberculosis in a patient with liver cirrhosis. Lechebnoe delo. 2015;2:81-84. Russian.
44. Janeway C.A. Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216. DOI: 10.1146/annurev.immunol.20.083001.084359
45. Kumagai Y., Takeuchi O., Akira S. Pathogen recognition by innate receptors. J Infect Chemother. 2008;14(2):86-92. DOI: 10.1007/s10156-008-0596-1
46. Aoyama T., Paik Y.H., Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract. 2010;2010:192543. DOI: 10.1155/2010/192543
47. Mencin A., Kluwe J., Schwabe R.F. Toll-like receptors as targets in chronic liver diseases. Gut. 2009;58(5):704720. DOI: 10.1136/gut.2008.156307
48. Soares J.B., Pimentel-Nunes P., Roncon-Albuquerque R., Leite-Moreira A. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int. 2010;4(4):659-672. DOI: 10.1007/s12072-0109219-x
49. De Creus A., Abe M., Lau A.H., Hackstein H., Raimondi G., Thomson A.W. Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin. J Immunol. 2005;174(4):20372045. DOI: 10.4049/jimmunol.174.4.2037
50. Shu S.A., Lian Z.X., Chuang Y.H., Moritoki Y., Comstock S.S., Zhong R.-Q., et al. The role of CD11c(+) hepatic dendritic cells in the induction of innate immune responses. Clin Exp Immunol. 2007;149(2):335-343. DOI: 10.1111/j.1365-2249.2007.03419.x
51. Yin M., Bradford B.U., Wheeler M.D., Uesugi T., Froh M., Goyert S.M., et al. Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol. 2001;166(7): 4737-4742. DOI: 10.4049/jimmunol.166.7.4737
52. Uesugi T., Froh M., Arteel G.E., Bradford B.U., Thurman R.G. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology. 2001;34(1):101-108. DOI: 10.1053/jhep.2001.25350
53. Castellano G., Stasi A., Intini A., Gigante M., Di Palma A.M., Divella C., et al. Endothelial dysfunction and renal fibrosis in endotoxemia-induced oliguric kidney injury: possible role of LPS-binding protein. Crit Care. 2014;18(5):520. DOI: 10.1186/s13054-014-0520-2
54. Appenrodt B., Grünhage F., Gentemann M.G., Thyssen L., Sauerbruch T., Lammert F. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology. 2010;51(4):13271333. DOI: 10.1002/hep.23440
55. Bruns T., Peter J., Reuken P.A., Grabe D.H., Schuldes S.R., Brenmoehl J., et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int. 2012;32(2):223-230. DOI: 10.1111/j.14783231.2011. 02561.x
56. Barreales M., Fernández I. Spontaneous bacterial peritonitis. Rev Esp Enferm Dig. 2011;103(5):255-263. DOI: 10.4321/s1130-01082011000500006
57. Ginès P., Schrier R.W. Renal failure in cirrhosis. 2009;361(13):1279-1290. DOI: 10.1056/NEJMra0809139
58. Tsai M.H., Peng Y.S., Chen Y.C., Liu N.-J., Ho Y.-P., Fang J.-T., et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43(4):673-681. DOI: 10.1002/hep.21101
59. Fukui H. How leaky gut and endotoxemia induce bacterial infection in cirrhosis and gastrointestinal hemorrhage? J Gastroenterol Hepatol. 2011;26(3):423-425. DOI: 10.1111/j.1440-1746.2011.06668.x
60. Goulis J., Armonis A., Patch D., Sabin C., Greenslade L., Burroughs A.K. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27(5):1207-1212. DOI: 10.1002/hep.510270504
61. Cervoni J.P., Thévenot T., Weil D., Muel E., Barbot O., Sheppard F., et al. C-reactive protein predicts shortterm mortality in patients with cirrhosis. J Hepatol. 2012;56(6):1299-1304. DOI: 10.1016/j.jhep.2011.12.030
62. Cervoni J.P., Amorós À., Bañares R., Montero J.L., Soriano G., Weil D., et al. Prognostic value of C-reactive protein in cirrhosis: external validation from the CANONIC cohort. Eur J Gastroenterol Hepatol. 2016;28(9):10281034. DOI: 10.1097/MEG.0000000000000676
63. Papp M., Vitalis Z., Altorjay I., Tornai I., Udvardy M., Harsfalvi J., et al. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. Liver Int. 2012;32(4):603-611. DOI: 10.1111/j.14783231.2011.02689.x
64. Lazzarotto C., Ronsoni M.F., Fayad L., Nogueira C.L, Bazzo M.L., Narciso-Schiavon J.L., et al. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol. 2013;12(4):599-607. PMID: 23813138
65. Dinic-Radovic V., Nagorni A., Brzacki V., Ristic L., RadovicM. Importance of certain pro-inflammatory indices in patients with liver cirrhosis and bacterial infection on prognosis and course of the disease. Med Arh. 2012;66(1):19-23. DOI: 10.5455/medarh.2012.66.19.23
66. Ximenes R.O., Farias A.Q., Scalabrini Neto A., Diniz M.A., Kubota G.T., Aben-Athar Ivo M.M., et al. Patients with cirrhosis in the ED: early predictors of infection and mortality. Am J Emerg Med. 2016;34(1):25-29. DOI: 10.1016/j.ajem.2015.09.004
67. Kadam N., Acharya S., Shukla S., Gupta K. Ascitic fluid high sensitive C-reactive protein (hs-CRP). A prognostic marker in cirrhosis with spontaneous bacterial peritonitis. J Clin Diagn Res. 2016;10(4):OC20-OC24. DOI: 10.7860/JCDR/2016/17931.7610
68. Tsiakalos A., Karatzaferis A., Ziakas P., Hatzis G. Acutephase proteins as indicators of bacterial infection in patients with cirrhosis. Liver Int. 2009;29(10):1538-1542. DOI: 10.1111/j.1478-3231.2009.02088.x
69. Lesińska M., Hartleb M., Gutkowski K., NowakowskaDuława E. Procalcitonin and macrophage inflammatory protein-1 beta (MIP-1β) in serum and peritoneal fluid of patients with decompensated cirrhosis and spontaneous bacterial peritonitis. Adv Med Sci. 2014;59(1):52-56. DOI: 10.1016/j.advms.2013.07.006
70. Bota D.P., Van Nuffelen M., Zakariah A.N., Vincent J.L. Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med. 2005;146(6):347-351. DOI: 10.1016/j.lab.2005.08.005
71. Park W.B., Lee K.D., Lee C.S., Jang H.C., Kim H.B, Lee H.S., et al. Production of C-reactive protein in Escherichia coliinfected patients with liver dysfunction due to liver cirrhosis. Diagn Microbiol Infect Dis. 2005;51(4):227-230. DOI: 10.1016/j.diagmicrobio.2004.11.014
72. Silvestre J.P., Coelho L.M., Póvoa P.M. Impact of fulminant hepatic failure in C-reactive protein? J Crit Care. 2010;25(4):657.e7-12. DOI: 10.1016/j.jcrc.2010.02.004
73. Connert S., Stremmel W., Elsing C. Procalcitonin is a valid marker of infection in decompensated cirrhosis. Z Gastroenterol. 2003;41(2):165-170. DOI: 10.1055/s2003-37314
74. Munford R.S. Detoxifying endotoxin: time, place and person. J Endotoxin Res. 2005;11(2):69-84. DOI: 10.1179/096805105X35161
75. Leventhal J.S., Schröppel B. Toll-like receptors in transplantation: sensing and reacting to injury. Kidney Int. 2012;81(9):826-832. DOI: 10.1038/ki.2011.498
76. Albillos A., de-la-Hera A., Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet. 2004;363(9421):1608-1610. DOI: 10.1016/S01406736(04)16206-5
77. Reiberger T., Ferlitsch A., Payer B.A., Mandorfer M., Heinisch B.B., Hayden H., et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911-921. DOI: 10.1016/j.jhep.2012.12.011
78. Agiasotelli D., Alexopoulou A., Vasilieva L., Hadziyannis E., Goukos D., Daikos G.L., et al. High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis. Liver Int. 2017;37(4):576-582. DOI: 10.1111/liv.13264
79. Giavarina D., Carta M. Determination of reference interval for presepsin, an early marker for sepsis. Biochem Med (Zagreb). 2015;25(1):64-68. DOI: 10.11613/BM.2015.007
80. Elefsiniotis I., Tsakiris S.A., Barla G., Tasovasili A, Vrachatis D., Mavrogiannis C. Presepsin levels in cirrhotic patients with bacterial infections and/or portal hypertension-related bleeding, presenting with or without acute kidney injury. Ann Gastroenterol. 2018;31(5):604612. DOI: 10.20524/aog.2018.0292
81. 81 Papp M., Tornai T., Vitalis Z., Tornai I., Tornai D., Dinya T. et al. Presepsin teardown – pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis. World J Gastroenterol. 2016;22(41):91729185. DOI: 10.3748/wjg.v22.i41.9172
82. Ishikura H., Nishida T., Murai A., Nakamura Y., Irie Y., Tanaka J., et al. New diagnostic strategy for sepsisinduced disseminated intravascular coagulation: a prospective single-center observational study. Crit Care. 2014;18(1):R19. DOI: 10.1186/cc13700
83. Bernardi M., Moreau R., Angeli P., Schnabl B., Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):12721284. DOI: 10.1016/j.jhep.2015.07.004
84. Bellot P., García-Pagán J.C., Francés R., Abraldes J.G., Navasa M., Pérez-Mateo M., et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52(6):20442052. DOI: 10.1002/hep.23918
85. Such J., Francés R., Muñoz C., Zapater P., Casellas J.A., Cifuentes A., et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology. 2002;36(1):135141. DOI: 10.1053/jhep.2002.33715
86. Francés R., Benlloch S., Zapater P., González J.M, Lozano B., Muñoz C., et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites [published correction appears in Hepatology. 2004;39(5):1464]. Hepatology. 2004;39(2):484-491. DOI: 10.1002/hep.20055
87. Krohn S., Böhm S., Engelmann C., Hartmann J., Brodzinski A., Chatzinotas A., et al. Application of qualitative and quantitative real-time PCR, direct sequencing, and terminal restriction fragment length polymorphism analysis for detection and identification of polymicrobial 16S rRNA genes in ascites. J Clin Microbiol. 2014;52(5):1754-1757. DOI: 10.1128/JCM.00552-14
88. Francés R., Muñoz C., Zapater P., Uceda F., Gascón I., Pascual S., et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut. 2004;53(6):860-864. DOI: 10.1136/gut.2003.027425
89. Francés R., Zapater P., González-Navajas J.M., Muñoz C., Caño R., Moreu R., et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology. 2008;47(3):978-985. DOI: 10.1002/hep.22083
90. Caro E., Francés R., Zapater P., Pascual S., Bellot P., Such J. Grade of soluble inflammatory response is mainly affected by circulating bacterial DNA concentrations in cirrhosis. Liver Int. 2016;36(10):1473-1480. DOI: 10.1111/liv.13118
91. Zapater P., Francés R., González-Navajas J.M., de la Hoz M.A, Moreu R., Pascual S., et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology. 2008;48(6):1924-1931. DOI: 10.1002/hep.22564
92. El-Naggar M.M., Khalil E.A., El-Daker M., Salama M.F. Bacterial DNA and its consequences in patients with cirrhosis and culture-negative, non-neutrocytic ascites. J Med Microbiol. 2008;57(12):1533-1538. DOI: 10.1099/jmm.0.2008/001867-0
93. Mortensen C., Karlsen S., Grønbæk H., Nielsen D.T, Frevert S., Clemmesen J.O., et al. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion. Liver Int. 2013;33(9):1309-1315. DOI: 10.1111/liv.12205
94. Engelmann C., Krohn S., Prywerek D., Hartmann J., Herbern A., Boehlig A., et al. Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival. Eur J Gastroenterol Hepatol. 2016;28(11):1285-1292. DOI: 10.1097/MEG.0000000000000712
95. Mitruka B.M. Application of gas chromatography in microbiology and medicine. М.: Medicina; 1978. 608 p. Russian.
96. Pavlov Ch.S. Modern approaches to the diagnosis and treatment of spontaneous bacterial peritonitis. Russian journal of gastroenterology, hepatology, coloproctology. 2002;5:10-19. Russian.
97. Vinnitskaya E.V. Spontaneous bacterial peritonitis: new approaches to diagnosis in alcoholic liver cirrhosis. Jeksperimental'naja i klinicheskaja gastrojenterologija. 2008;4:97-102. Russian.
98. Bruns T., Reuken P.A., Stengel S., Gerber L., Appenrodt B., Schade J.H., et al. The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection. Liver Int. 2016;36(8):1133-1142. DOI: 10.1111/liv.13095
99. Milevoj Kopcinovic L., Culej J., Jokic A., Bozovic M., Kocijan I. Laboratory testing of extravascular body fluids: national recommendations on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Part I – Serous fluids. Biochem Med (Zagreb). 2020;30(1):010502. DOI: 10.11613/BM.2020.010502
100. Burri E., Schulte F., Muser J., Meier R., Beglinger C. Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count. World J Gastroenterol. 2013;19(13):2028-2036. DOI: 10.3748/wjg.v19.i13.2028
101. Lutz P., Pfarr K., Nischalke H.D., Krämer B., Goeser F., Glässner A., et al. The ratio of calprotectin to total protein as a diagnostic and prognostic marker for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. Clin Chem Lab Med. 2015;53(12):2031-2039. DOI: 10.1515/cclm-2015-0284
102. Fernandes S.R., Santos P., Fatela N., Baldaia C., Marinho R.T., Proença H., et al. Ascitic calprotectin is a novel and accurate marker for spontaneous bacterial peritonitis. J Clin Lab Anal. 2016;30(6):1139-1145. DOI: 10.1002/jcla.21994
103. Kirkovskii V.V., Dzadzko A.M., Hapanovich V.N., Prilutskii P.S., Ryabtseva T.V. Changes in mean arterial pressure and total peripheral resistance during LPS sorption in patients with septic shock in the postoperative period of orthopedic liver transplantation. Zdravoohranenie. 2019;5:51-55. Russian.
104. Stadlbauer V., Krisper P., Aigner R., Haditsch B., Jung A., Lackner C., et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-onchronic liver failure. Crit Care. 2006;10(6):R169. DOI: 10.1186/cc5119
105. Sarin S.K., Choudhury A., Sharma M.K., Maiwall R., Al Mahtab M., Rahman S., et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update [published correction appears in Hepatol Int. 2019;13(6):826-828]. Hepatol Int. 2019;13(4):353390. DOI: 10.1007/s12072-019-09946-3

Views

0 Abstract

0 PDF

0 Crossref citations

Translocation of gut microbiota in liver cirrhosis: mechanisms, clinical significance, and markers

Abstract

Views

Shared

Cited by Crossref